Gilead Sciences GILD today announced results from a Phase
3 study, PHOTON-1, evaluating the investigational once-daily nucleotide
analogue sofosbuvir for the treatment of chronic hepatitis C virus (HCV)
infection among patients co-infected with HIV. In the trial, 76 percent
(n=87/114) of genotype 1 HCV treatment-naïve patients receiving 24 weeks
of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin
(RBV) achieved a sustained virologic response 12 weeks after completing
therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV
infection. These data will be presented this week during the 64th
Annual Meeting of the American Association for the Study of Liver
Diseases (The Liver Meeting 2013) in Washington, D.C.
Up to one-third of people
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in